Agios Pharmaceuticals, Inc. (AGIO)
34.16
-0.05
(-0.15%)
USD |
NASDAQ |
Sep 02, 16:00
34.16
0.00 (0.00%)
After-Hours: 17:53
Agios Pharmaceuticals Research and Development Expense (TTM) : 351.40M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 351.40M |
| March 31, 2026 | 342.68M |
| December 31, 2025 | 334.36M |
| September 30, 2025 | 329.01M |
| June 30, 2025 | 314.70M |
| March 31, 2025 | 299.83M |
| December 31, 2024 | 295.63M |
| September 30, 2024 | 290.28M |
| June 30, 2024 | 299.38M |
| March 31, 2024 | 290.66M |
| December 31, 2023 | 288.90M |
| September 30, 2023 | 281.30M |
| June 30, 2023 | 264.07M |
| March 31, 2023 | 269.21M |
| December 31, 2022 | 271.35M |
| September 30, 2022 | 273.96M |
| June 30, 2022 | 272.76M |
| March 31, 2022 | 260.19M |
| December 31, 2021 | 247.73M |
| September 30, 2021 | 233.47M |
| June 30, 2021 | 221.31M |
| March 31, 2021 | 213.32M |
| December 31, 2020 | 211.02M |
| September 30, 2020 | 258.47M |
| June 30, 2020 | 310.51M |
| Date | Value |
|---|---|
| March 31, 2020 | 366.23M |
| December 31, 2019 | 408.93M |
| September 30, 2019 | 398.46M |
| June 30, 2019 | 379.34M |
| March 31, 2019 | 358.68M |
| December 31, 2018 | 341.32M |
| September 30, 2018 | 324.73M |
| June 30, 2018 | 315.09M |
| March 31, 2018 | 308.17M |
| December 31, 2017 | 292.68M |
| September 30, 2017 | 280.14M |
| June 30, 2017 | 267.87M |
| March 31, 2017 | 238.86M |
| December 31, 2016 | 220.16M |
| September 30, 2016 | 192.42M |
| June 30, 2016 | 167.80M |
| March 31, 2016 | 153.42M |
| December 31, 2015 | 141.83M |
| September 30, 2015 | 139.76M |
| June 30, 2015 | 129.26M |
| March 31, 2015 | 115.08M |
| December 31, 2014 | 100.04M |
| September 30, 2014 | 80.46M |
| June 30, 2014 | 69.74M |
| March 31, 2014 | 60.45M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Biogen, Inc. | 1.736B |
| Insmed, Inc. | 860.84M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Exelixis, Inc. | 824.32M |